NATERA INC

Natera Inc. specializes in advanced genomic testing and molecular diagnostics for clinical and research applications, with a focused expertise in next-generation sequencing technologies. The company delivers tumor whole exome sequencing, peripheral blood ctDNA analysis, minimal residual disease detection, and targeted gene panel testing for kidney disease, leveraging high-throughput sequencing platforms and bioinformatics pipelines to generate clinically actionable insights. Their work supports precision oncology and inherited disease diagnostics, with strong capabilities in data transfer, reporting, and assay validation for complex liquid biopsy applications. Natera’s technical differentiators include integrated single-assay workflows, longitudinal monitoring solutions, and scalable genomic data management systems tailored for high-volume, high-accuracy laboratory environments. The contractor maintains a consistent, long-term relationship with the Department of Veterans Affairs, providing specialized genetic testing services across multiple task orders and contract modifications. Their work for the VA centers on enabling personalized veterans’ healthcare through molecular diagnostics, particularly in cancer surveillance and chronic disease management, demonstrating sustained operational reliability and adaptability to evolving clinical needs. Natera operates primarily within the Medical Laboratories NAICS 621511 category, positioning itself as a niche provider of clinical genomics services within the federal healthcare sector. Their focus on molecular diagnostics, liquid biopsy, and cancer genomics aligns with growing federal priorities in precision medicine and veteran-centric health innovation. Natera Inc. is a limited liability entity based in Austin, Texas, with no publicly disclosed federal certifications. The company’s geographic presence is centered in Texas, with its operational footprint defined by its ability to deliver complex laboratory services to federal clients through secure, compliant, and scalable diagnostic infrastructure.